ES2154303T3 - PHENYLINDOL COMPOUNDS. - Google Patents
PHENYLINDOL COMPOUNDS.Info
- Publication number
- ES2154303T3 ES2154303T3 ES94931520T ES94931520T ES2154303T3 ES 2154303 T3 ES2154303 T3 ES 2154303T3 ES 94931520 T ES94931520 T ES 94931520T ES 94931520 T ES94931520 T ES 94931520T ES 2154303 T3 ES2154303 T3 ES 2154303T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- phenylindol
- antipsytical
- extrapiramidal
- arylxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical class N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- -1 PHENYLINDOL COMPOUND Chemical class 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001484 cataleptigenic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Sewing Machines And Sewing (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyurethanes Or Polyureas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE PRESENTA UN COMPUESTO DE FENILINDOLA QUE TIENEN LA FORMULA GENERAL (I), EN DONDE R1-R4 SON INDEPENDIENTEMENTE HIDROGENO, DEUTERIO, HALOGENO, ALQUILO, ARILO, HIDROXIDO, ALCOXIDO, ARILOXIDO, ALQUILTIO Y ARILTIO; O R1 Y R2 Y/O R3 Y R4 CONSTITUYEN UN GRUPO OXO O TIOXO; O R1 Y R2 Y/O R3 Y R4, RESPECTIVAMENTE, SE UNEN ENTRE SI PARA FORMAR UN ANILLO ESPIRO DE ENTRE 3 Y 8 MIEMBROS; LOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES DE 5-HT{SUB,2}, NO CATALEPTOGENICOS "IN VIVO" Y MUESTRAN UN MODELO INDICATIVO DE EFECTO ANTIPSICOTICO. DE ESTA FORMA LOS COMPUESTOS PUEDEN SER UTILES EN EL TRATAMIENTO DE LA PSICOSIS, DEPRESION, SINTOMAS NEGATIVOS DE LA ESQUIZOFRENIA, HIPERTENSION O EFECTOS COLATERALES EXTRAPIRAMIDALES INDUCIDOS POR DROGAS ANTIPSICOTICAS.A PHENYLINDOL COMPOUND IS SUBMITTED WITH THE GENERAL FORMULA (I), WHERE R1-R4 IS INDEPENDENTLY HYDROGEN, DEUTERIO, HALOGEN, RENT, ARYL, HYDROXIDE, ALCOXIDE, ARYLXIDE, ALKYLTHYL AND ARYLTITIDE; O R1 AND R2 Y / O R3 AND R4 CONSTITUTE AN OXO OR THIOX GROUP; OR R1 AND R2 AND / OR R3 AND R4, RESPECTIVELY, JOIN BETWEEN TO FORM A SPIRIT RING BETWEEN 3 AND 8 MEMBERS; THE COMPOUNDS ARE ANTAGONISTS OF THE 5-HT {SUB, 2} RECEPTORS, NOT "IN VIVO" CATALEPTOGENIC AND SHOW AN INDICATIVE MODEL OF ANTIPSYTICAL EFFECT. IN THIS FORM, THE COMPOUNDS CAN BE USEFUL IN THE TREATMENT OF PSYCHOSIS, DEPRESSION, NEGATIVE SYMPTOMS OF SCHIZOPHRENIA, HYPERTENSION OR EXTRAPIRAMIDAL COLLATERAL EFFECTS INDUCED BY ANTIPSYTICAL DRUGS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK931234A DK123493D0 (en) | 1993-11-01 | 1993-11-01 | COMPOUNDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2154303T3 true ES2154303T3 (en) | 2001-04-01 |
Family
ID=8102507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94931520T Expired - Lifetime ES2154303T3 (en) | 1993-11-01 | 1994-10-28 | PHENYLINDOL COMPOUNDS. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5703087A (en) |
| EP (1) | EP0726898B1 (en) |
| JP (1) | JP3898219B2 (en) |
| KR (1) | KR100350550B1 (en) |
| CN (1) | CN1134149A (en) |
| AT (1) | ATE198199T1 (en) |
| AU (1) | AU683700B2 (en) |
| CA (1) | CA2175498C (en) |
| CZ (1) | CZ291403B6 (en) |
| DE (1) | DE69426462T2 (en) |
| DK (2) | DK123493D0 (en) |
| ES (1) | ES2154303T3 (en) |
| FI (1) | FI116623B (en) |
| GR (1) | GR3035462T3 (en) |
| HU (1) | HUT76063A (en) |
| IL (2) | IL111394A (en) |
| LV (1) | LV12805B (en) |
| NO (1) | NO309038B1 (en) |
| NZ (1) | NZ275086A (en) |
| PL (1) | PL176391B1 (en) |
| PT (1) | PT726898E (en) |
| RU (1) | RU2156249C2 (en) |
| SI (1) | SI0726898T1 (en) |
| SK (1) | SK281761B6 (en) |
| WO (1) | WO1995012591A1 (en) |
| ZA (1) | ZA948589B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| WO2001021614A1 (en) * | 1999-09-09 | 2001-03-29 | H. Lundbeck A/S | 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| US20070212412A1 (en) * | 2005-09-08 | 2007-09-13 | H. Lundbeck A/S | Stable solid formulation of sertindole |
| TW200821296A (en) * | 2006-06-01 | 2008-05-16 | Lundbeck & Co As H | Use of sertindole for the preventive treatment of suicidal behaviour |
| BR112012015868A2 (en) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | imidazolidinedione derivatives |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| EP2718285B1 (en) * | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| CN104334547B (en) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | Triazoles as KV3 inhibitors |
| BR112014028718A2 (en) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | hydantoin derivatives as kv3 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8908085D0 (en) * | 1989-04-11 | 1989-05-24 | Lundbeck & Co As H | New therapeutic use |
| DK152090D0 (en) * | 1990-06-22 | 1990-06-22 | Lundbaek A S H | PIPERIDYL-SUBSTITUTED INDEX DERIVATIVES |
-
1993
- 1993-11-01 DK DK931234A patent/DK123493D0/en not_active Application Discontinuation
-
1994
- 1994-10-25 IL IL11139494A patent/IL111394A/en not_active IP Right Cessation
- 1994-10-25 IL IL11139594A patent/IL111395A/en not_active IP Right Cessation
- 1994-10-28 US US08/635,905 patent/US5703087A/en not_active Expired - Fee Related
- 1994-10-28 JP JP51296895A patent/JP3898219B2/en not_active Expired - Fee Related
- 1994-10-28 PL PL94314181A patent/PL176391B1/en not_active IP Right Cessation
- 1994-10-28 CA CA002175498A patent/CA2175498C/en not_active Expired - Fee Related
- 1994-10-28 PT PT94931520T patent/PT726898E/en unknown
- 1994-10-28 RU RU96110902/04A patent/RU2156249C2/en not_active IP Right Cessation
- 1994-10-28 WO PCT/DK1994/000407 patent/WO1995012591A1/en not_active Ceased
- 1994-10-28 DK DK94931520T patent/DK0726898T3/en active
- 1994-10-28 AU AU80577/94A patent/AU683700B2/en not_active Ceased
- 1994-10-28 SK SK534-96A patent/SK281761B6/en not_active IP Right Cessation
- 1994-10-28 CZ CZ19961248A patent/CZ291403B6/en not_active IP Right Cessation
- 1994-10-28 NZ NZ275086A patent/NZ275086A/en not_active IP Right Cessation
- 1994-10-28 KR KR1019960702237A patent/KR100350550B1/en not_active Expired - Fee Related
- 1994-10-28 CN CN94193987A patent/CN1134149A/en active Pending
- 1994-10-28 EP EP94931520A patent/EP0726898B1/en not_active Expired - Lifetime
- 1994-10-28 SI SI9430356T patent/SI0726898T1/en unknown
- 1994-10-28 AT AT94931520T patent/ATE198199T1/en not_active IP Right Cessation
- 1994-10-28 ES ES94931520T patent/ES2154303T3/en not_active Expired - Lifetime
- 1994-10-28 HU HU9601144A patent/HUT76063A/en not_active Application Discontinuation
- 1994-10-28 DE DE69426462T patent/DE69426462T2/en not_active Expired - Fee Related
- 1994-11-01 ZA ZA948589A patent/ZA948589B/en unknown
-
1996
- 1996-04-30 NO NO961746A patent/NO309038B1/en not_active IP Right Cessation
- 1996-04-30 FI FI961844A patent/FI116623B/en active IP Right Grant
-
2001
- 2001-02-22 GR GR20010400296T patent/GR3035462T3/en not_active IP Right Cessation
- 2001-12-20 LV LV010178A patent/LV12805B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2154303T3 (en) | PHENYLINDOL COMPOUNDS. | |
| ES2062974T3 (en) | CEPHALOSPORIN COMPOUNDS, PREPARATION PROCEDURES AND ANTIBACTERIAL AGENTS. | |
| ATE160774T1 (en) | ANTIPSYCHOTIC BENZIMIDAZOLE DERIVATIVES | |
| ATE12497T1 (en) | TRICYCLIC AETHERS, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINES. | |
| ES2110225T3 (en) | ANTISICOTIC DERIVATIVES OF INDAZOL. | |
| ES2059893T3 (en) | DERIVATIVES OF DIFENILUREA. | |
| ES2064771T3 (en) | ANTAGONISTS OF MUSCARINIC RECEPTORS. | |
| CO4440567A1 (en) | COMPOUNDS OF FORMULA (I) BETA-ADRENERGIC RECEPTOR AGONISTS THAT HAVE USEFULNESS AS HYPOGLYCES, ANTIOBESITY AND OTHER AGENTS | |
| ES2029812T3 (en) | A PROCEDURE FOR PREPARING ALPHA-ALKYL-4-AMINO-3-QUINOLINE-METHANOLS AND 1- (4-ARALKYLAMINO-3-QUINOLYL) ALCANONAS. | |
| TR199801734T2 (en) | New arylglycinamide derivatives, production methods. | |
| PE133799A1 (en) | THROMBIN RECEPTOR ANTAGONISTS | |
| DK100588D0 (en) | 3-AMINO-DIHYDRO- (1) -BENZOPYRANES AND -BENZOTHIOPYRANES | |
| PE54294A1 (en) | DERIVATIVE OF 5-AMINOALKYL-1,4-BENZODIAZEPINE | |
| ES2159749T3 (en) | DERIVATIVES OF BENCILAMINO-2-METHYL-PROPANAMIDS 2- (4-SUBSTITUTES). | |
| PE20020144A1 (en) | DERIVATIVES OF PLEUROMUTILINS AS ANTIBACTERIAL AGENTS | |
| PE69398A1 (en) | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | |
| NO863507D0 (en) | 3-AMINO-DIHYDRO- (1) -BENXOPYRANES AND-BENZOTIOPYRANES. | |
| PE108498A1 (en) | SPYROCYCLIC LEAGUES OF A DOPAMINE RECEPTOR SUBTYPE | |
| ES2071479T3 (en) | DERIVATIVES OF INDANO. | |
| ES2063381T3 (en) | ANTAGONISTS OF MUSCARINIC RECEPTORS. | |
| PE25998A1 (en) | DERIVATIVES OF OCTAHIDRO-PIRROLO (1,2-a) -PIRAZINA 2,7-SUBSTITUTED | |
| ES2173866T3 (en) | HYDROISOQUINOLINE DERIVATIVES. | |
| ES2078519T3 (en) | CYCLIC HYDROXAMIC ACIDS AND THEIR USE. | |
| DE59108026D1 (en) | Phenylalkylaminoalkyl compounds and processes for their preparation and medicaments containing these compounds | |
| ES2168373T3 (en) | BICYCLE DERIVATIVES WITH RIGID AND ADAMANTAN CONFORMATION USEFUL AS ALFA-2-ADRENERGIC BLOCKING AGENTS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 726898 Country of ref document: ES |